AUS
NZ
UK
CA
USA
IND
Movement of the broader Australian markets is very sensitive to the overall health of global economy as well as to the news related to the trade war between the US and China. A permanent settlement of the war could positively impact the sentiments of market players and, as a result, they can decide to make deployments towards equities. Performance of the Australian economy also influences the performance of stock markets. Coming to the performance on September 20, 2019, S&P/ASX200 witnessed a rise of 13.3 points or 0.2% on an intraday basis to end the session at 6730.8. On the same day, All Ordinaries increased by 13.8 points or 0.2% to settle the dayâs session at 6839.
We would now be having a look at how the stocks performed on Australian Securities Exchange (or ASX) on September 20, 2019. Premier Investments Limited (ASX: PMV) witnessed a rise of 15.341% to settle at A$18.120 per share, while IOOF Holdings Limited (ASX: IFL) rose by 7.928% to end at A$5.990 per share. On the same day, Speedcast International Limited (ASX: SDA) and Sigma Healthcare Limited (ASX: SIG) ended the session in red, witnessing a fall of 5.645% and 4.478%, respectively, on an intraday basis.
We have provided important information on four energy sector stocks (i.e. PDN, VEA, SOL, ORG) for the investors and we advise them to have a glimpse of the same. In order to have a look, please click here.
Swift Media Agrees New Financing
Swift Media Limited (ASX: SW1) has wrapped up a new financing agreement with 2 institutional investors to raise up to $3.6 million.
L1 Capital Global Opportunities Master Fund as well as Lind Global Macro Fund LP would be providing a total funding of $3.6 million to Swift that would be drawn down in four tranches, each of $900k, at the 75-day intervals.
Neurenâs Executive Chairman-Richard Treagus Presents Upcoming Milestones
As the market players are aware, Neuren Pharmaceuticals Limited (ASX: NEU) is approaching the last quarter with key milestones anticipated for business.
- NEU and North American partner-ACADIA plan to commence the âLAVENDERâ Phase 3 trial of trofinedtide in Rett syndrome.
- The company also expects FDA (or U.S. Food and Drug Administration) to complete review of 3 applications of Orphan Drug designation for NNZ-2591 in Phelan-McDermid, Angelman, and Pitt syndromes, that NEU had submitted at July 2019 end.
- Orphan drug designation is a crucial commercial milestone, which once granted would add substantial value as well as momentum in respect of NEUâs plans to move into the clinical trials in 2020.
Centuria Industrial REIT Dividend Update
Centuria Industrial REIT (ASX: CIP) came forward and made an announcement about an unfranked distribution amounting to 4.675 cents per unit for the quarter ending September 2019. The Distribution Reinvestment Plan remains active for the September distribution. The following dates are important for investors:
- Ex-date for the distribution is September 27, 2019
- Record date is September 30, 2019
- Payment date is October 30, 2019.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
